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Abstract
Purpose of Review Chronic cough, defined in adults as one lasting longer than 8 weeks, is among the commonest clinical
problems encountered by doctors both in general practice and in hospital. It can exist as a distinct clinical problem or as a
prominent and troublesome symptom for patients with common pulmonary conditions including asthma, chronic obstructive
pulmonary disease and idiopathic pulmonary fibrosis.
Recent Findings Chronic cough impacts considerably on patients’ daily-life activities and many patients are left frustrated by
what they see as a complete lack of awareness among their doctors as how to treat their condition. Some of this arises from limited
levels of physician knowledge about managing cough as a clinical problem but also because there are no very effective treatments
that specifically target cough.
Summary In this article, we review the current clinical thinking regarding cough and the treatments that are currently used and
those undergoing clinical development.
Keywords Cough . Cough receptor . Pharmacological targets . Novel . Ion channel
Introduction
Under normal physiological circumstances, coughing occurs
with the primary purpose of protecting the lung from inhaled
irritants and clearing unwanted airway secretions. Clinically,
this defensive neural reflex can become dysregulated leading
to episodes of cough evoked by relatively innocuous stimuli.
This causes significant problems for those affected and is one
of the most common reasons why people seek medical atten-
tion [1].
For clinical purposes, cough is defined as acute, sub-acute
or chronic depending on its duration. An acute cough typically
lasts no more than 3 weeks and is generally the result of a viral
upper respiratory tract infection (URTI) associated with the
common cold. Sub-acute cough lasts between 3 and 8 weeks
and is likely due to a slowly resolving post-viral cough. In
adult patients, a cough persisting for more than 8 weeks is
termed ‘chronic’ and can occur as an isolated clinical problem
or associated with common respiratory and non-respiratory
conditions such as chronic obstructive pulmonary disease
(COPD), asthma, idiopathic pulmonary fibrosis (IPF),
gastro-oesophageal reflux disease (GORD) and post-nasal
drip or rhinosinusitis. Sometimes, despite extensive investiga-
tion and trials of empirical therapy, the cause for cough re-
mains unexplained and in such instances is termed an idio-
pathic, or unexplained chronic cough [2, 3].
The prevalence of chronic cough may affect up to 13% of
the general population and is associated with significant phys-
ical and psychological morbidity [4–8]. In a recent survey of
almost 2000 people living with chronic cough, respondents
reported their cough had impacted adversely on daily-life ac-
tivities leading to many feeling fed-up and depressed [9].
Crucially, the majority reported undergoing numerous consul-
tations with different physicians and receiving many unsuc-
cessful therapeutic trials.
The increasing recognition of chronic cough as an impor-
tant clinical problem has led to the development of guidelines
to improve clinical care [10–12]. The underlying principle
recommended in these guidelines is first to consider common
respiratory diseases associated with obvious chest radiology
and lung function abnormalities and then systematically
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evaluate the patient for other common causes such as asthma,
reflux disease and upper airway disorders. While this ap-
proach is helpful and treatments such as inhaled steroids and
anti-reflux therapy do help to control cough, a significant pro-
portion of patients remain troubled [3]. In response to increas-
ing numbers of patients referred for evaluation of cough, a
number of specialist clinics have been set up within the UK,
throughout Europe, the USA and Australasia. With a more
detailed and expert assessment, there has been a fundamental
change in understanding of the complex clinical aspects of
cough. Central to this has been the notion that cough develops
as a result of inflammation causing damage to the nerve cells
(neuroinflammation) that conduct the cough signal from the
lungs to the brain resulting in the clinical state now termed,
cough hypersensitivity syndrome (CHS). Understanding the
mechanisms responsible for this nerve damage (neuropathy)
will be key to developing better treatments [13].
Cough Hypersensitivity Syndrome
The term ‘Cough Hypersensitivity Syndrome’ was first pro-
posed by a European Respiratory Society Task Force and is
defined as a ‘clinical syndrome characterised by troublesome
coughing triggered by low levels of thermal, mechanical or
chemical exposure’ [14]. The underlying concept is that the
basal protective cough reflex transforms to a heightened state
such that it is now triggered by low-level stimuli that would
not usually cause cough. This state reflects precisely the clin-
ical features reported by patients with CHS in so far as chang-
es in ambient temperature, taking a deep breath, or talking,
exposure to aerosol sprays or eating crumbly dry food are all
sufficient to trigger bouts of coughing. The mechanisms re-
sponsible for this clinical state have yet to be determined but
may parallel other disease concepts such as neuropathic pain.
Following this line of thinking, cough triggered by innocuous
stimuli might be similar to allodynia and excessive coughing
in response to a noxious exposure (hypertussia) could be con-
sidered equivalent to hyperalgesia.
Although the causes of chronic cough vary, cough reflex
hypersensitivity is likely to be a shared clinical and mechanis-
tic characteristic. Therefore, while CHS may be present in a
wide variety of conditions, common mechanisms likely un-
derpin its development, offering great potential for the devel-
opment of effective therapies.
Treatment of Chronic Cough
The recognition that chronic cough is characterised by hyper-
sensitivity of the peripheral and central neural pathways in-
volved in cough has expanded the range of potential therapeu-
tic targets currently under evaluation. Here, we provide an
update on these therapies with a focus on proposed site of
action (peripheral or central) and preclinical and clinical find-
ings to date. To do this, we undertook a detailed appraisal of
published peer-reviewed research over the past 5 years
(January 2013–December 2018) using PubMed for articles
in English. The search terms included ‘cough’ plus ‘receptor’,
‘pharmacological targets’, ‘novel’, ‘ion channel’. We also re-
ferred to publications accumulated because of our involve-
ment in chronic cough research and treatment over the past
15 years. Articles resulting from these searches and relevant
references cited in those articles were also reviewed. We also
reviewed ClinicalTrials.gov over the last 5 years, and detail
from this has been summarised in an accompanying table.
Treatments with a Peripheral Site of Action
Attenuating the heightened cough sensitivity while retaining
the protective physiological capacity of the cough reflex is
critical in the development of effective treatments. Sensory
nerves of the airways express a variety of receptors and ion
channels that when activated trigger cough. It seems logical
that these channels/receptors may represent therapeutic targets
for cough (Fig. 1). Here, we provide brief overview of expe-
rience with a number of these putative targets.
TRP Channels
Transient receptor potential (TRP) channels were first discov-
ered and described in Drosophila in the 1960s but have since
become important targets in chronic cough [15].Manipulation
of TRP channels on nociceptive neurons is proposed as an
attractive strategy in the treatment of pain, and several drug
developments targeting pain are focusing on these receptors.
TRP channels are present in abundance in the airways and are
expressed in many cell types of the airway including primary
sensory afferent nerves, epithelial cells and smooth muscle
cells [16].
TRP channels are cation channels comprising six trans-
membrane spanning domains with a pore between the fifth
and sixth domains which allows the entry of calcium into a
cell [17]. TRP channels are polymodal and directly activated
by changes in temperature, chemicals, mechanical stimula-
tion, pH and osmolality, which may evoke nociceptive re-
sponses including cough. The TRP channel superfamily en-
compasses 28 members that can be divided into 6 subfamilies
based on sequence homology [17]. Of particular interest in
relation to cough are members of the vanilloid (TRPV1,
TRPV4), anykrin (TRPA1) and melastatin (TRPM8) families.
TRPV1 TRPV1 was the first channel to be considered as a key
regulator of cough. TRPV1 is a polymodal channel activated
by a variety of irritants including high temperature (> 43 °C),
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inflammatorymediators (e.g. prostaglandins, bradykinin), low
pH (< 5.9) and capsaicin [17, 18]. Capsaicin, the pungent in-
gredient of hot chilli peppers, readily induces cough on inha-
lation. Recent randomised clinical trials of the TRPV1 antag-
onists, SB-705498 and XEN-D0501, have shown marked re-
duction in capsaicin-induced cough reflex sensitivity but
failed to reduce cough frequency in chronic cough patients
[19, 20]. Based on evidence to date, it is unlikely that
TRPV1 will be an effective therapeutic target for chronic
cough.
TRPA1 The TRPA1 channel is activated by a range of phys-
ical and chemical factors including cold temperatures (<
17 °C), mechanical stimulation, inflammatory mediators
(e.g. prostaglandins, bradykinin) and acrolein (a component
of cigarette smoke) [21, 22]. In both animal models and
healthy humans, the TPRA1 agonist cinnamaldehyde in-
duces a dose-dependent cough response [23]. Animal studies
have shown effectiveness of TRPA1 antagonists in reducing
cough in response to tussive challenges. The TRPA1 antag-
onist HC-030031 reduces cough responses to both exoge-
nous and endogenous activators of TRPA1 in guinea pigs
[24, 25]. Glenmark have developed a TRPA1 inhibitor,
GRC 17536, which showed inhibition of citric acid-
induced cough in guinea pigs [26]. However, in a double-
blinded placebo-controlled study, there was no reduction in
Fig. 1 Illustration of central and peripheral targets for antitussive agents.
Current therapies in development that target the peripheral component of
cough are transient receptor potential (TRP) channels (TRPV1, TRPV2,
TRPV4 and TRPM8), purinergic receptors (P2X3) and voltage-gated
sodium channels (NaV). Peripheral sensory neurons project to regions
of the brainstem including the nucleus tractus solitarius (nTS).
Currently available centrally acting drugs target predominately μ-opioid
receptors and N-methyl-D-aspartate (NMDA) receptors. Neurokinin-1
receptor (NK-1R) antagonists and agonists of the alpha7 (α7) subtype
of nicotinic acetylcholine receptors (nAChRs) are in early stages of
evaluation. Figure adapted from Smith JA et al. N Engl J Med 2016;
375: 1544–51
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cough frequency over 24 h or no reduction in citric acid-
induced cough [16].
TRPV4 TRPV4 is recognised as an osmosensor and responds
to diverse stimuli including non-noxious temperatures (27–
35 °C), shear stress and mechanical stimulation. TRPV4 acti-
vation has been shown to be associated with the release of
adenosine 5′-triphosphate (ATP). The TRPV4 agonist,
GSK1016790a, induced depolarisation of vagus nerves in
both animal and human tissue and induced cough in conscious
guinea pigs which was blocked by the TRPV4 antagonist
HC067047 [27, 28]. The mechanism underlying TRPV4-
induced ATP release has yet to be elucidated but a role for
P2X3 receptors has been proposed [27]. However, a clinical
trial with the TRPV4 antagonist, GSK2798745, was terminat-
ed early, presumably due to lack of efficacy.
TRPM8
TRPM8 is activated by cooling compounds such as menthol,
icilin and eucalyptol. Although thought to play a role in cough
induced by the inhalation of cold air, the TRPM8 agonist
menthol also has protective and soothing effects and is a com-
ponent of many over-the-counter cough remedies [29, 30].
The evidence for an antitussive role of TRPM8 is inconclusive
and modulation of TRPM8 remains to be investigated as a
potential target for chronic cough.
To date, pharmacological modulation of TRP channels for
the treatment of cough has been disappointing. It remains to be
seen if newer agents or strategies represent realistic options for
the field of cough.
Purinergic Receptors
Purinergic receptors include subtypes of P2X ion channel re-
ceptors which are activated by ATP and have received consid-
erable attention recently as potential targets for the treatment
of pain and cough. ATP is released as a result of cellular stress
due to injury or infection and in lung conditions such as asth-
ma or COPD, elevated airway levels have been reported [31,
32]. P2X3 receptors expressed on airway sensory afferent
nerves are considered to have a role in development of me-
chanical allodynia and hyperalgesia in animal models of pain
[33]. Gefapixant (MK-7264), previously known as AF-219, is
a P2X3 receptor antagonist recently shown to reduce cough
frequency in a small placebo-controlled, crossover study of
patients with unexplained chronic cough. High doses
(600 mg bd) of the compound were used in this study, and
all participants reported taste disturbances (hypogeusia or
dysgeusia) [34]. A phase 2b study of gefapixant at lower doses
has reported efficacy with less taste disturbance [35].
Currently, this compound represents the most promising ther-
apeutic target in development.
Voltage-Gated Sodium Channels
Voltage-gated sodium channels (NaV) mediate the initiation
and propagation of action potentials in afferent sensory nerves
and represent a potential therapeutic target for cough.
Lidocaine, a non-selective NaV channel blocker, attenuates
the cough induced chemically by citric acid and capsaicin in
awake guinea pigs [36, 37]. It has also been used clinically to
alleviate cough and has been reported to be safe [38].
However, there are concerns regarding serious side effects of
lidocaine including cardiac arrhythmias [39, 40]. A more
targeted approach to NaV blockade seems sensible and of nine
subtypes, NaV1.7, NaV1.8 and NaV1.9 are known to be
expressed on vagal sensory neurons that innervate the lung
and are likely to be involved in initiating cough [41, 42].
Selective inhibition of the NaV1.7 channel reduces excitabil-
ity and sensory nerve activity and inhibits mechanically in-
duced cough in guinea pigs [43, 44]. Recently, however, the
results of a clinical trial of a novel blocker targeting NaV1.7
(GSK2339345) suggested no antitussive effect [45].
Treatments with a Central Site of Action
Sensory input from the upper and lower airways to the
brainstem is relayed to higher brain regions where they
modulate the varying sensory and motor responses that
accompany coughing. The mechanisms underpinning the
development of CHS may be akin to those described in
pain where disordered peripheral and central neurophys-
iology are thought to be responsible for a variety of
chronic pain syndromes. Chronic cough patients appear
to have altered brain activity with evidence of both
central sensitisation and dysfunctional inhibitory control
[46]. A greater understanding of this disordered central
processing is required and more selective targeting of
pathways will be key to improved therapeutic control
of troublesome coughing. Currently, the drugs used to
treat or control cough that exert their therapeutic effect
centrally do so at the expense of undesirable effects
including sedation, respiratory depression and addiction.
Here, we provide a brief overview of some of the com-
mon drugs with presumed central action used in treat-
ment of chronic cough and highlight some more specific
agents in early phase development.
Opiates (Morphine Sulphate/Codeine/Tramadol)
Opiates have been used to control cough for over 200 years.
The notion that opiates are an effective cough suppressant has
arisen from old studies in humans and animal studies [47, 48].
One commonly used drug is codeine, regarded as a weak
opioid and found naturally in extracts of the poppy. The
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evidence for its efficacy is conflicting and given its
unfavourable side effect profile, codeine is not an ideal anti-
tussive [49–51].
The only randomised controlled study of opiates conducted
in patients with chronic intractable cough was undertaken by
Morice and colleagues which showed that 5 mg of morphine
sulphate twice daily for 2 months was an effective antitussive
[52]. More recently, the antitussive properties of tramadol, an
opioid medication with a similar structure to codeine and mor-
phine, have been investigated in a pilot study and shown to be
effective [53].
Dextomethorphan, which is an active ingredient of many
popular brands of ‘over-the-counter’ cough preparations, is
considered to have opiate properties. However, as its primary
use is to control acute cough associated with the common
cold, it is outside the scope of this review. However, a detailed
review of this compound and other centrally acting drugs used
for acute cough is available elsewhere [54].
GABA-Related Compounds (Gabapentin, Pregabalin)
Gabapentin and pregabalin are centrally acting neuromodula-
tors primarily used for the treatment of neuropathic pain and
epilepsy [55]. Both are structurally related to the inhibitory
neurotransmitter, γ-aminobutyric acid (GABA), although
their precise mode of action is unknown. They are known to
modulate the release of neurotransmitters including substance
P and may exert antitussive effects through attenuation of
post-synaptic excitability [56]. One randomised placebo-
controlled trial has shown that treatment of refractory chronic
cough with gabapentin is both effective and well tolerated
[57]. These efficacy claims have been supported in a recent
systematic literature review [58].
Pregabalin has also been shown to improve cough in pa-
tients with what was termed sensory laryngeal neuropathy,
and more recently, the combination of pregabalin and speech
pathology treatment (SPT) was shown to be more effective in
improving cough quality of life than SPT alone [59, 60].
Based on the existing evidence, gabapentin has recently re-
ceived recommendation in the CHEST Guideline and Expert
Panel Report as a treatment option for chronic cough [3].
N-Methyl-D-Aspartate (NMDA) Receptors
N-methyl-D-aspartate (NMDA) receptors are expressed
within the peripheral and central nervous system and are
believed to play a role in the synaptic transmission of
cough-associated vagal afferents which project from the
lungs to the brainstem [61]. Dextromethorphan is thought
to exert in effect at least in part through activation of
NMDA receptors [62]. Preclinical studies have also sug-
gested the antitussive effects of memantine, an NMDA re-
ceptor channel blocker used in the treatment of Alzheimer’s
disease [63, 64]. Despite this promising data, a recent small
open-label pilot study of a novel NMDA receptor antagonist,
V3381, showed only marginal efficacy and concerns regard-
ing tolerability [65].
Amitriptyline
Amitriptyline is used for the treatment of depression and lower
doses are also prescribed for the treatment of chronic neuro-
pathic pain. This drug is an inhibitor of serotonin re-uptake but
may also have effects on the muscarinic, adrenergic and his-
taminergic systems [66, 67]. Treatment of chronic cough with
amitriptyline is reported to reduce cough, and in an open-label
study of treatment for 10 days, improvements in cough fre-
quency and severity when compared with codeine were re-
ported [68]. However, in another study conducted over a lon-
ger duration (2 months), the efficacy of amitriptyline in pa-
tients with chronic cough was short-lived, and the majority of
subjects discontinued treatment [69].
Tachykinin Receptor Antagonists
The tachykinins, substance P, neurokinin A and neurokinin B
are released both from the peripheral endings of afferent
nerves (predominately C-fibres) and from central neural struc-
tures. The tachykinin receptor, neurokinin 1 receptor has
gained attention as a target for chronic cough treatment. The
NK1R antagonist, aprepitant, has been shown to reduce cough
in patients with lung cancer [70]. A pilot study of serlopitant, a
centrally acting NK1R antagonist, resulted in significant im-
provements in objective cough frequency and sustained re-
ductions in daytime cough frequency [71]. Currently,
serlopitant is undergoing further clinical evaluation
(Table 1). Orvepitant, another NK1 receptor antagonist, is also
in phase 2 clinical trials (Table 1).
Nicotinic Acetylcholine Receptors
Nicotinic acetylcholine receptors, or nAChRs, respond to the
neurotransmitter acetylcholine and to nicotine and are found
in the central and peripheral nervous system. In a recent study
of healthy non-smokers, marked antitussive effects of
nicotine-containing vapours produced by e-cigarettes were re-
ported [72]. It is now believed that the alpha7 (α7) subtype of
the nAChRs, activating GABAergic interneurons in the
brainstem, is responsible for the antitussive effect of nicotine
[73]. Bradanicline, a selective agonist of the α7 subunit is
currently being tested as a potential treatment for chronic
cough in a phase 2 randomised, double-blind, dose-
escalation and crossover study.
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Other Medications for the Treatment
of Chronic Cough
Azithromycin
A study by Hodgson et al. investigated the potential effects of
azithromycin, a macrolide, on chronic cough [74]. Treatment
with azithromycin for 8 weeks failed to improve health status of
chronic cough patients when compared with placebo. This
study however suggested there may be potential benefit of
macrolide use in the treatment of cough associated with asthma.
PA-101 Cromolyn Sodium Formulation
PA-101 is a novel formulation of cromolyn sodium and thought
to act as a mast cell stabiliser. It has undergone study in idio-
pathic chronic cough and in patients with pulmonary fibrosis,
where cough is often a troublesome symptom. In a randomised
placebo-controlled trial where PA-101was delivered via a high-
efficiency eFlow nebuliser, no improvement in chronic idio-
pathic cough patients was observed [75]. However, the study
did report reduction in cough in patients with idiopathic pulmo-
nary fibrosis. These findings suggest some degree of heteroge-
neity in mechanisms responsible for CHS.
Conclusion
Chronic cough is an extremely common clinical problem that
can exist in isolation or as the dominant symptom for patients
across a wide range of common chronic respiratory conditions.
Chronic cough is often difficult to control, largely because of
the lack of effective medicines. Over the last two or three de-
cades, there has been enormous progress in terms of optimising
clinical evaluation, and gaining consensus on how to best man-
age patients with troublesome cough. There have also been
important developments in the mechanistic understanding of
cough and elucidating the associated neurobiology, and with
this have come a number of promising therapeutic targets.
Some of these are at advanced stages of clinical development
with drugs targeting the P2X3 receptor most promising.
However, many challenges remain and partnerships are re-
quired, bringing clinicians and patients, scientists and industry
together with government agencies to overcome these. This
approach is likely to speed up drug discovery with the ultimate
aim of providing better treatments for cough patients.
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